Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer: a Phase II Study

NCT06787911 is registered in ClinicalTrials.gov with Yu Wang as lead sponsor.

NCT NCT06787911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06787911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer: a Phase II Study
Lead sponsor
Yu Wang
Phase
Phase 2
Overall status
Recruiting
Start date
July 24, 2024
Completion date
September 30, 2026
Enrollment
14 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid cancer